Position in ACAD
as of Mar 31, 2026
· filed May 1, 2026
Position Value
$1,810,784
-$968,979 QoQ
Shares Held
81,347
-21.8% QoQ
Ownership
0.048%
of shares outstanding
% of Portfolio
0.29%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2023
11 quarters on record
Voting authority
Sole 16%
Shared 0%
None 84%
Common Shares in ACAD Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Phocas Financial Corp. holds $6,718,190 across 5 Biotechnology names. ACAD ranks #1 (27.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ACAD |
Acadia Pharmaceuticals Inc
This page
|
81,347 | $1,810,784 | |
| 2 | ZVRA |
Zevra Therapeutics, Inc.
|
159,423 | $1,485,822 | |
| 3 | PTCT |
Ptc Therapeutics, Inc.
|
19,875 | $1,354,083 | |
| 4 | ARQT |
Arcutis Biotherapeutics, Inc.
|
50,299 | $1,185,044 | |
| 5 | ADMA |
Adma Biologics, Inc.
|
97,942 | $882,457 |
All Filings in ACAD
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,810,784 | 81,347 | Shares | Sole | 2026-05-01 | |
| 2025-12-31 | $2,779,763 | 104,072 | Shares | Sole | 2026-01-26 | |
| 2025-09-30 | $2,226,679 | 104,343 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $2,203,936 | 102,176 | Shares | Sole | 2025-08-06 | |
| 2025-03-31 | $1,696,894 | 102,161 | Shares | Sole | 2025-05-09 | |
| 2024-12-31 | $1,978,331 | 107,811 | Shares | Sole | 2025-03-05 | |
| 2024-09-30 | $926,106 | 60,215 | Shares | Sole | 2024-11-07 | |
| 2024-06-30 | $1,039,951 | 63,997 | Shares | Sole | 2024-07-24 | |
| 2024-03-31 | $1,205,677 | 65,207 | Shares | Sole | 2024-05-01 | |
| 2023-12-31 | $2,096,423 | 66,957 | Shares | Sole | 2024-01-30 | |
| 2023-09-30 | $1,369,000 | 65,691 | Shares | Sole | 2023-10-10 | |
| No filing history on record for this holder in this stock. | ||||||